App Logo
menu

Menu

close
expand_more

Myeloma Resources

expand_less
/
/
FDA Grants First anti-BCMA CAR T Approval in Multiple Myeloma for Abecma
FDA Grants First anti-BCMA CAR T Approval in Multiple Myeloma for Abecma
Posted Apr 09, 2021

The FDA today approved the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma, bringing a completely new and personalized immunotherapy drug class to the myeloma clinic. The approval opens an exciting door to a completely new era in myeloma care. The new one-time treatment, called Abecma, (also known as ide-cel) was approved based on data from the KarMMA trial, where 72% of patients achieved a deep and rapid response. 

The treatment uses your own cells which are engineered to target BCMA, found on the surface of myeloma cells. Patients who are eligible to receive Abecma include relapsed or refractory patients who have received four or more prior lines of treatment that include an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 monoclonal antibody. The suggested dose will range from 300 to 460 x 106 CAR-positive T cells.  

Patients who have relapsed after using these three types of myeloma drugs (called triple-class refractory patients), are typically considered to be higher risk patients. Other drugs when tested alone in clinical trials typically show a 30% response rate. Patients are showing responses to CAR T therapies in the 75-95% rates, even for highly relapsed disease. To have such a large percentage of patients respond to this therapy is remarkable.

 

Finding Abecma Treatment Centers and Support

 

Support for Abecma is available on the Cell Therapy 360 website, a digital service platform to support Abecma patients and treating physicians. More programs will be offered to provide support for Abecma. Because administering CAR T therapy can be complicated, Abecma will be avaialble at certified treatment centers.

Additionally, a Risk Evaluation and Mitigation Strategy (REMS) program will be implemented at certified centers to support appropriate use of Abecma including training on the management of cytokine release syndrome and neurologic toxicities

To read the full press release including full side effect information, click here. 

<a href="https://healthtree.org/aml/community">Find more myeloma news and information on www.myelomacrowd.org</a>

More Myeloma 101 Articles

Article Image Thank Your Myeloma Doctor on National Doctor Day During Myeloma Awareness Month Article Image BCMA and Other Targets: Register Now for the Myeloma Crowd Round Table Webcast on April 10 Article Image Helpful Resources for Multiple Myeloma Patients Considering Stem Cell Transplants

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811